Heart attack survivors with TET2 gene change may benefit from colchicine
NCT ID NCT07362966
First seen Jan 24, 2026 · Last updated Jun 23, 2026 · Updated 25 times
Summary
This pilot study is testing whether the drug colchicine can reduce artery plaque in 120 heart attack survivors who have a specific gene change (TET2). Participants take colchicine or standard care for 12 months. The goal is to see if this gene change can guide personalized treatment to prevent future heart problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
General Hospital of Northern Theater Command
RECRUITINGShenyang, Liaoning, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
colchicine
What this could lead to
If successful, this could show that a simple anti-inflammatory drug like colchicine works better for people with certain gene changes, leading to more personalized heart attack prevention.
What could go wrong
This is a small pilot study (120 people) testing a specific gene marker. The results may not apply to everyone, and colchicine can cause side effects like stomach upset. It's too early to know if this approach will improve outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.